Relatro 25 Capsule

About Relatro 25 Capsule

Relatro 25 is a capsule made by Square Pharmaceuticals PLC. It contains 25 mg of Dantrolene Sodium, a centrally acting skeletal muscle relaxant. Doctors prescribe it to help manage long-term muscle stiffness linked to certain nerve and spinal cord conditions.

There are 3 brands of Dantrolene Sodium listed in Bangladesh.

What is Relatro 25 Capsule?

Relatro 25 is a 25 mg capsule of Dantrolene Sodium from Square Pharmaceuticals PLC, grouped among centrally acting skeletal muscle relaxants. It acts on the muscle itself rather than at the nerve-muscle junction, helping to ease the tight, stiff muscles that can follow upper motor neuron problems such as spinal cord injury, stroke, cerebral palsy or multiple sclerosis. It is used for long-term spasticity, particularly when stiffness holds back a person's rehabilitation. It is a prescription medicine, so the doctor decides whether it suits you, the dose and how long you take it, and checks your response over time.

Uses of Relatro 25

Relatro 25 is used to control the signs of chronic spasticity that come from upper motor neuron disorders, including spinal cord injury, stroke, cerebral palsy and multiple sclerosis. It can be particularly helpful for people whose rehabilitation has been slowed by spasticity. It is not a general muscle pain remedy. Only a doctor can confirm whether this medicine is appropriate for your condition and what course you need.

How to use Relatro 25

Take Relatro 25 exactly as your doctor prescribes, with the dose and schedule set for you alone. Your doctor may start low and adjust step by step while watching how you respond, and may change the plan based on that. Swallow the capsule as directed and do not change the amount or stop it on your own. Ask your doctor or pharmacist if you are unsure how to take it or what to do about a missed dose.

Side effects of Relatro 25

Drowsiness, dizziness, weakness, tiredness, general discomfort and diarrhoea are among the side effects reported with Dantrolene. These often appear early in treatment and may ease, and the doctor can adjust the plan. Diarrhoea can sometimes be severe and may mean the medicine has to be paused or stopped. Tell your doctor about any side effect that bothers you or does not settle, and get medical help for severe diarrhoea.

Safety and precautions

Relatro 25 should not be used by anyone with active liver disease such as hepatitis or cirrhosis. Liver problems, including serious ones, can occur with Dantrolene, so the doctor will weigh the benefits and may stop treatment if no benefit is seen in good time. Drowsiness can affect driving and hazardous work, and alcohol or other sedatives may add to it. Sunlight exposure can cause a skin reaction, so take care in the sun. In pregnancy it is used only if the benefit justifies the risk, and it should not be used while breastfeeding. Tell your doctor about liver problems, pregnancy, breastfeeding or other medicines before starting.

Frequently asked questions

Is Relatro 25 safe during pregnancy or breastfeeding?

It is in pregnancy category C, meaning it is used in pregnancy only when the possible benefit justifies the possible risk to the baby. It should not be used by nursing mothers. Tell your doctor if you are pregnant, planning a pregnancy or breastfeeding before taking it.

What is Relatro 25 used for and what kind of medicine is it?

Relatro 25 is a centrally acting skeletal muscle relaxant containing Dantrolene Sodium. It is used for long-term spasticity caused by upper motor neuron disorders such as spinal cord injury, stroke, cerebral palsy or multiple sclerosis, especially when stiffness is holding back rehabilitation.

How should I store Relatro 25?

Keep Relatro 25 in a cool, dry place away from light. Follow the storage instructions on the pack, keep it out of reach of children, and ask your pharmacist if you are unsure how to dispose of capsules you no longer need.

Can I drive or go out in the sun while taking Relatro 25?

Drowsiness and dizziness can occur, so avoid driving or hazardous work until you know how the medicine affects you. It may also make the skin sensitive to sunlight, so take care with sun exposure. Ask your doctor for advice about your own activities.

Indications

In Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuronal disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patients whose functional ... Read moreIn Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuronal disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patients whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrolene therapy. In such instances, information regarding improvement should be solicited from the patient. Brief withdrawal of Dantrolene for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.

A decision to continue the administration of Dantrolene on a long-term basis is justified if introduction of the drug into the patient's regimen:
  • produces a significant reduction in painful and/or disabling spasticity such as clonus, or
  • permits a significant reduction in the intensity and/or degree of nursing care required, or
  • rids the patient of any annoying manifestation of spasticity considered important by the patient himself.
In Malignant Hyperthermia: Oral Dantrolene is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Oral Dantrolene should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.

Pharmacology

Dantrolene produces relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. In skeletal muscle, Dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of Ca++ from the sarcoplasmic reticulum.

Dosage & Administration

For Use in Chronic Spasticity:
  • Adults: The following gradual titration schedule is suggested. Some patients will not respond until higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.
  • Starting dose is 25 mg twice per day and it can be increased to 25-50 mg per day per week. Maximum accepted dosage is 400 mg per day.
  • Paediatric Patients: The following gradual titration schedule is suggested. Some patients will not respond until higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.
  • 0.5 mg/kg once daily for seven days, then 0.5 mg/kg 3 times for 7 days, 1 mg/kg 3 times for 7 days, 2 mg/kg 3 times a day, Therapy with a dose 4 times daily may be necessary for some individuals.
For Malignant Hyperthermia
  • Preoperatively: Administer 4 to 8 mg/kg/day of oral Dantrolene in 3 or 4 divided doses for one or two days prior to surgery, with the last dose being given approximately 3 to 4 hours before scheduled surgery with a minimum of water.
  • Post Crisis Follow-up: Oral Dantrolene should also be administered following a malignant hyperthermia crisis, in doses of 4 to 8 mg/kg per day in four divided doses, for a one to three day period to prevent recurrence of the manifestations of malignant hyperthermia.

Interaction

Drowsiness may occur with Dantrolene therapy, and the concomitant administration of CNS depressants such as sedatives and tranquilizing agents may result in further drowsiness. Hepatotoxicity has occurred more often in women over 35 years of age receiving concomitant estrogen therapy.

Contraindications

Active hepatic disease, such as hepatitis and cirrhosis.

Side Effects

The most frequently occurring side effects of Dantrolene have been drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. These are generally transient, occurring early in treatment, and can often be obviated by beginning with a low dose and increasing dosage gradually until an optimal regimen is established. Diarrhea may be severe and may necessitate temporary withdrawal of Dantrolene therapy. If diarrhea recurs upon readministration of Dantrolene, therapy should probably be withdrawn permanently

Pregnancy & Lactation

Pregnancy Category C. Dantrolene capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dantrolene should not be used in nursing mothers.

Precautions & Warnings

In view of the potential for liver damage in long-term Dantrolene use, therapy should be stopped if benefits are not evident within 45 days. Patients should be cautioned against driving a motor vehicle or participating in hazardous occupations while taking Dantrolene. Caution should be exercised in the concomitant administration of tranquilizing agents. Dantrolene might possibly evoke a photosensitivity reaction; patients should be cautioned about exposure to sunlight while taking it. It is important to recognize that fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with Dantrolene therapy. At the start of Dantrolene therapy, it is desirable to do liver function studies (SGOT, SGPT, alkaline phosphatase, total bilirubin) for a baseline or to establish whether there is preexisting liver disease. Liver function studies (e.g., SGOT or SGPT) should be performed at appropriate intervals during Dantrolene therapy. Some patients have revealed a return to normal laboratory values in the face of continued therapy while others have not. If symptoms compatible with hepatitis, accompanied by abnormalities in liver function tests or jaundice appear, Dantrolene should be discontinued. If caused by Dantrolene and detected early, the abnormalities in liver function characteristically have reverted to normal when the drug was discontinued. Dantrolene therapy has been reinstituted in a few patients who have developed clinical and/ or laboratory evidence of hepatocellular injury. If such reinstitution of therapy is done, it should be attempted only in patients who clearly need Dantrolene and only after previous symptoms and laboratory abnormalities have cleared. The patient should be hospitalized and the drug should be restarted in very small and gradually increasing doses. Laboratory monitoring should be frequent and the drug should be withdrawn immediately if there is any indication of recurrent liver involvement. Dantrolene should be used with particular caution in females and in patients over 35 years of age in view of apparent greater likelihood of drug-induced, potentially fatal, hepatocellular disease in these groups.

Dantrolene should be used with caution in patients with impaired pulmonary function, and in patients with severely impaired cardiac function due to myocardial disease. It should be used with caution in patients with a history of previous liver disease or dysfunction.

Storage Conditions

Store in a cool & dry place, protected from light.

Alternative brands of Dantrolene Sodium

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.